MBX Biosciences (MBX) Gains from Investment Securities (2023 - 2026)

MBX Biosciences has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $715178.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $715178.0, up 2548.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $715178.0 (down 42.69% YoY), and the FY2025 annual result was $4.6 million, up 2314.57% from the prior year.
• Gains from Investment Securities came in at $715178.0 for Q1 2026 at MBX Biosciences, down from $2.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $4.3 million in Q2 2025 to a low of $27000.0 in Q1 2025.
• The 4-year median for Gains from Investment Securities is $200348.0 (2024), against an average of $968758.2.
• Across the five-year window, Gains from Investment Securities tumbled 82.91% in 2025 and soared 2548.81% in 2026, its largest moves.
• MBX Biosciences' Gains from Investment Securities stood at $140000.0 in 2023, then surged by 515.0% to $861000.0 in 2024, then soared by 230.89% to $2.8 million in 2025, then slumped by 74.9% to $715178.0 in 2026.
• The last three Gains from Investment Securities figures came in at $715178.0 (Q1 2026), $2.8 million (Q4 2025), and $193519.0 (Q3 2025), per Business Quant data.